Chahla Jorge, Alland Jeremy A, Verma Nikhil N
Jorge Chahla, MD, PhD, Midwest Orthopaedics at Rush, Chicago, IL. Jeremy A. Alland, MD, Midwest Orthopaedics at Rush, Chicago, IL. Nikhil N. Verma, MD, Midwest Orthopaedics at Rush, Chicago, IL.
Orthop Nurs. 2018 Nov/Dec;37(6):379-381. doi: 10.1097/NOR.0000000000000502.
Biological-based therapies are rapidly expanding for different musculoskeletal conditions because of their potential benefits including their minimal invasiveness, capacity for unprecedented healing, and potential for rapid recovery. In this regard, although several approaches have been reported in the literature, most of the body of the literature is increasingly based on platelet-rich plasma, bone marrow aspirate concentrate, and cell-based therapy studies. Although further basic science and clinical research is needed to elucidate the long-term outcome of these therapies in the treatment of several injuries, there is compelling evidence for their use for certain indications. The purpose of this article was to review the main aspects of bone marrow aspirate concentrate, which is one of the few forms of stem cell delivery approved by the Food and Drug Administration, and, furthermore, to critically assess the current evidence-based recommendations and identify potential avenues for development.
基于生物的疗法正迅速扩展至不同的肌肉骨骼疾病治疗领域，这是因为它们具有潜在益处，包括微创性、实现前所未有的愈合能力以及快速恢复的潜力。在这方面，尽管文献中已报道了多种方法，但大部分文献越来越多地基于富血小板血浆、骨髓抽吸浓缩物和细胞疗法研究。尽管需要进一步的基础科学和临床研究来阐明这些疗法在治疗多种损伤方面的长期效果，但有令人信服的证据表明它们可用于某些适应症。本文的目的是回顾骨髓抽吸浓缩物的主要方面，它是美国食品药品监督管理局批准的少数几种干细胞递送形式之一，此外，对当前基于证据的建议进行批判性评估，并确定潜在的发展途径。
